

Aubagio® (teriflunomide) – First-time generic

- On March 13, 2023, <u>Zydus</u>, <u>Accord</u>, Dr. Reddy's, <u>Aurobindo</u>, <u>Glenmark</u>, <u>Teva</u>, <u>Sandoz</u>, <u>Viatris</u> and <u>Camber launched</u> AB-rated generic versions of Genzyme's <u>Aubagio (teriflunomide)</u> tablets.
- Aubagio is approved for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- Aubagio carries a boxed warning for hepatotoxicity and embryofetal toxicity.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.